{
  "metadata": {
    "timestamp": "2025-12-16T19:26:27.535217",
    "genes": [
      "AFAP1L2",
      "COL4A3",
      "FERMT1",
      "VIPR2",
      "AL512308.1",
      "CALCRL",
      "REPS2",
      "FGF12",
      "CCDC26",
      "OTOGL",
      "ELMO1",
      "PCDH15",
      "COL4A4",
      "THSD4",
      "FA2H",
      "LRRC7",
      "PLPP4",
      "PLA2G4A",
      "AR",
      "LINC00689",
      "TNS3",
      "BCAS1",
      "DLL3",
      "KCNIP3",
      "MIR503HG",
      "ANO3",
      "PLAAT1",
      "MEGF11",
      "GSG1L",
      "UGT8",
      "COL20A1",
      "ALCAM",
      "C2orf27A",
      "LHFPL3-AS1",
      "CA10",
      "SLC5A4",
      "ADAMTS17",
      "DCT",
      "CHST9",
      "NRSN1",
      "AC110285.1",
      "CCND1",
      "TRPC4",
      "TACR1",
      "TNR",
      "SOX6",
      "PDE4A",
      "GPR17",
      "ARPP21",
      "MYRF",
      "PRKG2",
      "LINC01268",
      "LINC01322",
      "AC023282.1",
      "EYA1",
      "ERBB3",
      "LRRC3B",
      "DISC1",
      "BRINP1",
      "SLC8A3",
      "SLIT1",
      "ATP13A5",
      "LINC00320",
      "SMOC1",
      "LIN28B",
      "CACNA1E",
      "OMG",
      "LAMB4",
      "SLC26A7",
      "GFPT2",
      "PDE7B",
      "FRG1-DT",
      "PODN",
      "PCSK2",
      "FAM160A1",
      "PRSS12",
      "HS6ST2",
      "PAPPA",
      "DOCK10",
      "ITGA9",
      "DLL1",
      "DGKB",
      "OR4N2",
      "CSMD3",
      "CRYBG3",
      "MDGA2",
      "SEMA3E",
      "CLDN11",
      "KIF21B",
      "NKD1",
      "AQP4",
      "GHR",
      "AGMO",
      "AC068308.1",
      "MOG",
      "TMPRSS9",
      "USP43",
      "MIR217HG",
      "LRFN5",
      "UGDH",
      "AL139231.1",
      "AL136114.1",
      "AC005909.2",
      "MYRIP",
      "ANO4",
      "TMEM132C",
      "AC077690.1",
      "AL031293.1",
      "AC104051.2"
    ],
    "context": "malignant glioblastoma cells",
    "provider": "perplexity",
    "model": "sonar-deep-research",
    "source": "scripts/run_deepsearch.py",
    "preset": null,
    "template": null,
    "custom_prompt_used": false,
    "provider_override": null,
    "model_override": null,
    "reasoning_effort_override": null,
    "search_recency_override": null,
    "timeout_seconds": 180,
    "effective_provider": "offline",
    "effective_model": "offline",
    "project": "glioblastoma_ds_auto",
    "query": "11_OPC_like_1",
    "source_tag": "deepsearch",
    "resolve_citations": true,
    "citation_flags": {
      "validate": true,
      "scrape": false,
      "pdf": true,
      "topic_validation": false
    }
  },
  "raw_response": {
    "markdown": "## Question\n\nPerform comprehensive literature analysis for the following gene list in the specified biological context.\n\n**Gene List**: [\"AFAP1L2\", \"COL4A3\", \"FERMT1\", \"VIPR2\", \"AL512308.1\", \"CALCRL\", \"REPS2\", \"FGF12\", \"CCDC26\", \"OTOGL\", \"ELMO1\", \"PCDH15\", \"COL4A4\", \"THSD4\", \"FA2H\", \"LRRC7\", \"PLPP4\", \"PLA2G4A\", \"AR\", \"LINC00689\", \"TNS3\", \"BCAS1\", \"DLL3\", \"KCNIP3\", \"MIR503HG\", \"ANO3\", \"PLAAT1\", \"MEGF11\", \"GSG1L\", \"UGT8\", \"COL20A1\", \"ALCAM\", \"C2orf27A\", \"LHFPL3-AS1\", \"CA10\", \"SLC5A4\", \"ADAMTS17\", \"DCT\", \"CHST9\", \"NRSN1\", \"AC110285.1\", \"CCND1\", \"TRPC4\", \"TACR1\", \"TNR\", \"SOX6\", \"PDE4A\", \"GPR17\", \"ARPP21\", \"MYRF\", \"PRKG2\", \"LINC01268\", \"LINC01322\", \"AC023282.1\", \"EYA1\", \"ERBB3\", \"LRRC3B\", \"DISC1\", \"BRINP1\", \"SLC8A3\", \"SLIT1\", \"ATP13A5\", \"LINC00320\", \"SMOC1\", \"LIN28B\", \"CACNA1E\", \"OMG\", \"LAMB4\", \"SLC26A7\", \"GFPT2\", \"PDE7B\", \"FRG1-DT\", \"PODN\", \"PCSK2\", \"FAM160A1\", \"PRSS12\", \"HS6ST2\", \"PAPPA\", \"DOCK10\", \"ITGA9\", \"DLL1\", \"DGKB\", \"OR4N2\", \"CSMD3\", \"CRYBG3\", \"MDGA2\", \"SEMA3E\", \"CLDN11\", \"KIF21B\", \"NKD1\", \"AQP4\", \"GHR\", \"AGMO\", \"AC068308.1\", \"MOG\", \"TMPRSS9\", \"USP43\", \"MIR217HG\", \"LRFN5\", \"UGDH\", \"AL139231.1\", \"AL136114.1\", \"AC005909.2\", \"MYRIP\", \"ANO4\", \"TMEM132C\", \"AC077690.1\", \"AL031293.1\", \"AC104051.2\"]\n\n**Biological Context**: malignant glioblastoma cells\n\n**Analysis Strategy**:\n1. Search current scientific literature for functional roles of each gene in the input list\n2. Identify clusters of genes that act together in pathways, processes, or cellular states\n3. Treat each cluster as a potential gene program within the list\n4. Interpret findings in light of both normal physiological roles and disease-specific alterations\n5. Prioritize well-established functions with strong literature support, but highlight emerging evidence if contextually relevant.\n\n**Guidelines**:\n* Anchor all predictions in either the normal physiology and development of the cell type and tissue specified in the context OR the alterations and dysregulations characteristic of the specified disease\n* Connect gene-level roles to program-level implications\n* Consider gene interactions, regulatory networks, and pathway dynamics\n* Highlight cases where multiple genes collectively strengthen evidence\n* Ensure all claims are backed by experimental evidence with proper attribution\n\n**Output**: Respond with JSON conforming to the provided schema - no prose, no markdown.  If you are unable to respond with JSON alone, make sure the text includes tables or fragments of schema compliant that unambiguously capture the elements and their associations that would be captured if returning JSON schema.\n\n```json\n{\n    \"$schema\": \"http://json-schema.org/draft-07/schema#\",\n    \"title\": \"Gene Program Functional Analysis\",\n    \"description\": \"Comprehensive literature-based functional analysis of gene lists in specific biological contexts. Perform systematic analysis to identify gene programs - clusters of genes acting together in pathways, processes, or cellular states. For each program, predict functional implications for the specified cell type in the context of the provided disease and tissue environment. Prioritize well-established functions with strong literature support, but highlight emerging evidence if contextually relevant. Rank predictions higher when multiple genes from input list act in same process and when most/all required pathway components are present.\",\n    \"type\": \"object\",\n    \"required\": [\n        \"context\",\n        \"input_genes\",\n        \"programs\",\n        \"version\"\n    ],\n    \"definitions\": {\n        \"atomic_term\": {\n            \"type\": \"object\",\n            \"required\": [\n                \"name\",\n                \"citation\",\n                \"genes\"\n            ],\n            \"properties\": {\n                \"name\": {\n                    \"type\": \"string\",\n                    \"description\": \"A minimal component of the gene program, representing a single biological process or cell component.\"\n                },\n                \"citations\": {\n                    \"type\": \"array\",\n                    \"items\": {\n                        \"$ref\": \"#/definitions/citation\"\n                    },\n                    \"description\": \"list of citations supporting the role of the listed genes in the name biological process or cell component\"\n                },\n                \"genes\": {\n                    \"type\": \"array\",\n                    \"items\": {\n                        \"type\": \"string\"\n                    },\n                    \"description\": \"Genes of the program whose products are involved in this biological process or cell component.\"\n                }\n            },\n            \"additionalProperties\": false\n        },\n        \"citation\": {\n            \"type\": \"object\",\n            \"required\": [\n                \"source_id\"\n            ],\n            \"properties\": {\n                \"source_id\": {\n                    \"type\": \"string\"\n                },\n                \"notes\": {\n                    \"type\": \"string\",\n                    \"description\": \"Why this citation supports the claim.\"\n                }\n            },\n            \"additionalProperties\": false\n        }\n    },\n    \"properties\": {\n        \"context\": {\n            \"type\": \"object\",\n            \"required\": [\n                \"cell_type\",\n                \"disease\"\n            ],\n            \"properties\": {\n                \"cell_type\": {\n                    \"type\": \"string\",\n                    \"description\": \"Extract and specify the name or names of the primary cell type(s) from the provided biological context. Use standard cell type terminology. Leave blank if not specified.\"\n                },\n                \"disease\": {\n                    \"type\": \"string\",\n                    \"description\": \"Extract and specify the disease or pathological condition from the provided biological context (e.g., 'IDH-mutant astrocytoma', 'Alzheimer disease', 'multiple sclerosis'). Use standard disease terminology. Leave blank if not specified.\"\n                },\n                \"tissue\": {\n                    \"type\": \"string\",\n                    \"description\": \"Extract and specify the tissue or anatomical location if mentioned in the biological context (e.g., 'brain', 'cerebral cortex', 'hippocampus'). Leave blank if not specified.\"\n                }\n            },\n            \"additionalProperties\": false\n        },\n        \"input_genes\": {\n            \"type\": \"array\",\n            \"items\": {\n                \"type\": \"string\",\n                \"minLength\": 1\n            },\n            \"minItems\": 1,\n            \"uniqueItems\": true\n        },\n        \"programs\": {\n            \"type\": \"array\",\n            \"minItems\": 1,\n            \"items\": {\n                \"type\": \"object\",\n                \"required\": [\n                    \"program_name\",\n                    \"description\",\n                    \"predicted_cellular_impact\",\n                    \"evidence_summary\",\n                    \"significance_score\",\n                    \"citations\",\n                    \"supporting_genes\"\n                ],\n                \"description\": \"A gene program, relevant to the provided context. Avoid programs that group 2 or more loosely related processes\",\n                \"properties\": {\n                    \"program_name\": {\n                        \"type\": \"string\",\n                        \"minLength\": 1,\n                        \"description\": \"Provide a concise, descriptive name for this gene program that captures its primary biological function or pathway. Use 2-5 words maximum.\"\n                    },\n                    \"description\": {\n                        \"type\": \"string\",\n                        \"minLength\": 1,\n                        \"description\": \"A more detailed description of the gene program.\"\n                    },\n                    \"atomic_biological_processes\": {\n                        \"type\": \"array\",\n                        \"description\": \"A list of atomic biological process terms extracted from the description.\",\n                        \"items\": {\n                            \"$ref\": \"#/definitions/atomic_term\"\n                        }\n                    },\n                    \"atomic_cellular_components\": {\n                        \"type\": \"array\",\n                        \"description\": \"A list of atomic cellular component terms extracted from the description.\",\n                        \"items\": {\n                            \"$ref\": \"#/definitions/atomic_term\"\n                        }\n                    },\n                    \"predicted_cellular_impact\": {\n                        \"type\": \"array\",\n                        \"minItems\": 1,\n                        \"items\": {\n                            \"type\": \"string\",\n                            \"description\": \"Concise bullet-level impacts (e.g., ‘enhanced focal adhesion signaling’)\"\n                        }\n                    },\n                    \"evidence_summary\": {\n                        \"type\": \"string\",\n                        \"minLength\": 1\n                    },\n                    \"significance_score\": {\n                        \"description\": \"A value between 0 and 1 that ranks this gene program by the number of supporting genes, the number of supporting references and relevance to the context.\",\n                        \"type\": \"number\",\n                        \"minimum\": 0.0,\n                        \"maximum\": 1.0\n                    },\n                    \"citations\": {\n                        \"description\": \"Array of citations supporting the role of the listed genes in this gene program.\",\n                        \"type\": \"array\",\n                        \"minItems\": 1,\n                        \"items\": {\n                            \"$ref\": \"#/definitions/citation\"\n                        }\n                    },\n                    \"supporting_genes\": {\n                        \"type\": \"array\",\n                        \"minItems\": 1,\n                        \"items\": {\n                            \"type\": \"string\"\n                        },\n                        \"uniqueItems\": true\n                    },\n                    \"required_genes_not_in_input\": {\n                        \"description\": \"Genes required for this program that are NOT present in the input genes.\",\n                        \"type\": \"object\",\n                        \"properties\": {\n                            \"genes\": {\n                                \"type\": \"array\",\n                                \"items\": {\n                                    \"type\": \"string\"\n                                }\n                            },\n                            \"citations\": {\n                                \"type\": \"array\",\n                                \"minItems\": 1,\n                                \"items\": {\n                                    \"$ref\": \"#/definitions/citation\"\n                                }\n                            }\n                        }\n                    }\n                },\n                \"additionalProperties\": false\n            }\n        },\n        \"method\": {\n            \"type\": \"object\",\n            \"description\": \"Optional trace of how programs were derived\",\n            \"properties\": {\n                \"clustering_basis\": {\n                    \"type\": \"array\",\n                    \"items\": {\n                        \"type\": \"string\"\n                    },\n                    \"description\": \"e.g., pathway databases, co-citation, PPI, co-expression\"\n                },\n                \"notes\": {\n                    \"type\": \"string\"\n                }\n            },\n            \"additionalProperties\": false\n        },\n        \"version\": {\n            \"type\": \"string\"\n        }\n    },\n    \"additionalProperties\": false\n}\n\n```\n\n## Output\n\n<think>\nThis is a complex query asking me to analyze a large gene list in the context of malignant glioblastoma cells. The user is providing many search results related to GBM, glioblastoma biology, transcriptional programs, and various cellular processes.\n\nLet me first organize my approach:\n\n1. **Understanding the context**: Malignant glioblastoma cells (GBM) - specifically referring to IDH-wildtype glioblastoma\n2. **The gene list**: 120 genes provided\n3. **The task**: Identify clusters of genes (programs) that work together in pathways/processes/cellular states\n4. **Output format**: Must be JSON conforming to the provided schema\n\nLet me analyze the search results to understand what's known about GBM biology:\n\nFrom the search results, I can identify key themes:\n- **Spatial transcriptomics findings** [1][16]: GBM shows spatially organized cellular states - mesenchymal (MES)-like in tumor core, AC/NPC/OPC-like in infiltrated regions. Notch signaling is upregulated in infiltrative cells.\n- **Transcription factors ASCL1 and OLIG2** [2]: Drive GBM initiation, regulate cell type specification, control plasticity\n- **Lipid-laden macrophages** [3]: Recycle myelin to fuel mesenchymal GBM progression\n- **Multilayered transcriptional architecture** [4]: Multiple malignant programs, tumor-associated macrophage interactions\n- **Neurodevelopmental hijacking** [5]: Infiltrative GBM cells activate OPC-like programs with increased invasivity, NOTCH signaling, synaptic activity\n- **Axonal injury** [6]: Described as targetable driver of GBM progression\n- **Collagens and ECM** [19][22]: Type IV collagen associated with vasculature, progression markers\n- **Myelin and oligodendrocyte genes**: UGT8, MOG, MYRF [27][28][29][30] - oligodendrocyte markers, dysregulated in GBM\n\n\n- **Neuronal signaling pathways** [43][46]: Neurons support GBM growth via neuroligin-3 secretion, creating a pro-tumoral microenvironment\n- **Aquaporin channels** [55][58]: AQP4 regulates edema formation, cell migration capacity, and astrocytic functions\n- **Receptor tyrosine kinase signaling** [32][35][39][42]: FGF/FGFR and EGFR pathways drive proliferation and survival\n- **Cell cycle machinery** [37][40]: CCND1 and CDCA7L control proliferative capacity\n- **Integrin-mediated adhesion** [8]: ITGA9 and FERMT1 facilitate cell-matrix interactions and migration\n- **Developmental programs** [2][14][15][34]: SOX genes, OLIG2, ASCL1, and EYA1 establish neural progenitor-like states that promote invasion and plasticity\n- **Notch-driven migration**: DLL1 and DLL3 activate invasion programs through developmental signaling cascades\n\nThe gene set maps onto distinct functional modules: oligodendrocyte differentiation genes (UGT8, MOG, MYRF, CLDN11) suggest lineage commitment pathways, while axonal guidance molecules (SLIT1, SEMA3E, KIF21B) and integrin components coordinate directional migration. Transcriptional regulators like SOX6, OLIG2, and EYA1 maintain neural progenitor identity, which correlates with aggressive tumor behavior and therapeutic resistance.\n\nIon channels and transporters (CACNA1E, ANO3, AQP4, SLC family members) regulate cellular excitability and osmotic balance, while lipid metabolism enzymes (PLA2G4A, DGKB, FA2H) support membrane remodeling during migration. Synaptic adhesion molecules (LRRC7, ALCAM, MDGA2) and extracellular matrix proteins (collagen IV, LAMB4) establish cell-cell and cell-matrix interactions that influence tumor cell behavior. Growth factor signaling through FGF12 and ERBB3, combined with neuropeptide receptor TACR1, suggests responsiveness to developmental cues that promote invasion and plasticity. I'm identifying distinct functional programs from the gene expression patterns. The oligodendrocyte lineage cluster centers on myelin-related genes with strong developmental literature support. Notch signaling through DLL1 and DLL3 maintains stemness properties in infiltrative populations, supported by multiple studies showing Notch upregulation in these cells. The infiltrative state appears to recapitulate OPC developmental programs, particularly through SOX6 and related factors. Synaptic interaction genes like LRRC7, ALCAM, and MDGA2 suggest neuronal engagement drives tumor progression. Finally, ion channel and transporter genes including AQP4, CACNA1E, and various SLC family members regulate cellular osmotic balance and calcium signaling during migration and edema formation.\n\nBeyond these, I'm seeing cell cycle drivers like CCND1 and CDCA7L that directly promote proliferation. The ECM remodeling program involves collagen genes and associated proteases that facilitate invasion. Integrin signaling through ITGA9 and FERMT1 coordinates adhesion and migration. Lipid metabolism genes including PLA2G4A and UGT8 point to myelin recycling as an energy source. Growth factor receptors like ERBB3 and FGF12 activate downstream proliferative cascades.\n</think>\n\n```json\n{\n  \"context\": {\n    \"cell_type\": \"malignant glioblastoma cells\",\n    \"disease\": \"IDH-wildtype glioblastoma (GBM)\",\n    \"tissue\": \"brain\"\n  },\n  \"input_genes\": [\n    \"AFAP1L2\", \"COL4A3\", \"FERMT1\", \"VIPR2\", \"AL512308.1\", \"CALCRL\", \"REPS2\", \"FGF12\", \"CCDC26\", \"OTOGL\", \"ELMO1\", \"PCDH15\", \"COL4A4\", \"THSD4\", \"FA2H\", \"LRRC7\", \"PLPP4\", \"PLA2G4A\", \"AR\", \"LINC00689\", \"TNS3\", \"BCAS1\", \"DLL3\", \"KCNIP3\", \"MIR503HG\", \"ANO3\", \"PLAAT1\", \"MEGF11\", \"GSG1L\", \"UGT8\", \"COL20A1\", \"ALCAM\", \"C2orf27A\", \"LHFPL3-AS1\", \"CA10\", \"SLC5A4\", \"ADAMTS17\", \"DCT\", \"CHST9\", \"NRSN1\", \"AC110285.1\", \"CCND1\", \"TRPC4\", \"TACR1\", \"TNR\", \"SOX6\", \"PDE4A\", \"GPR17\", \"ARPP21\", \"MYRF\", \"PRKG2\", \"LINC01268\", \"LINC01322\", \"AC023282.1\", \"EYA1\", \"ERBB3\", \"LRRC3B\", \"DISC1\", \"BRINP1\", \"SLC8A3\", \"SLIT1\", \"ATP13A5\", \"LINC00320\", \"SMOC1\", \"LIN28B\", \"CACNA1E\", \"OMG\", \"LAMB4\", \"SLC26A7\", \"GFPT2\", \"PDE7B\", \"FRG1-DT\", \"PODN\", \"PCSK2\", \"FAM160A1\", \"PRSS12\", \"HS6ST2\", \"PAPPA\", \"DOCK10\", \"ITGA9\", \"DLL1\", \"DGKB\", \"OR4N2\", \"CSMD3\", \"CRYBG3\", \"MDGA2\", \"SEMA3E\", \"CLDN11\", \"KIF21B\", \"NKD1\", \"AQP4\", \"GHR\", \"AGMO\", \"AC068308.1\", \"MOG\", \"TMPRSS9\", \"USP43\", \"MIR217HG\", \"LRFN5\", \"UGDH\", \"AL139231.1\", \"AL136114.1\", \"AC005909.2\", \"MYRIP\", \"ANO4\", \"TMEM132C\", \"AC077690.1\", \"AL031293.1\", \"AC104051.2\"\n  ],\n  \"programs\": [\n    {\n      \"program_name\": \"Oligodendrocyte differentiation and myelin formation\",\n      \"description\": \"A developmental transcriptional program that specifies cells toward the oligodendrocyte lineage and promotes myelination. This program includes master transcriptional regulators (MYRF, SOX6), structural myelin proteins (MOG, OMG, BCAS1, CLDN11), and enzymes essential for myelin lipid synthesis (UGT8, FA2H). In GBM context, dysregulation of this program reflects aberrant recapitulation of developmental processes and may be associated with cells occupying an uncommitted developmental state.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Myelin protein expression and trafficking\",\n          \"citations\": [\n            {\n              \"source_id\": \"28\",\n              \"notes\": \"MYRF is essential transcriptional factor for myelin gene activation including MBP, PLP, MAG, MOG\"\n            },\n            {\n              \"source_id\": \"49\",\n              \"notes\": \"MOG is late-stage oligodendrocyte marker, important for myelin sheath completion\"\n            },\n            {\n              \"source_id\": \"52\",\n              \"notes\": \"MOG appears late in oligodendrocyte maturation, serves as marker of mature state\"\n            }\n          ],\n          \"genes\": [\n            \"MYRF\",\n            \"MOG\",\n            \"OMG\",\n            \"BCAS1\",\n            \"CLDN11\"\n          ]\n        },\n        {\n          \"name\": \"Myelin lipid biosynthesis\",\n          \"citations\": [\n            {\n              \"source_id\": \"27\",\n              \"notes\": \"UGT8 catalyzes galactosylceramide synthesis, key constituent of myelin sheaths; aberrantly upregulated in aggressive tumors\"\n            },\n            {\n              \"source_id\": \"30\",\n              \"notes\": \"UGT8 expression associated with tumor aggressiveness and metastatic potential in breast cancer\"\n            }\n          ],\n          \"genes\": [\n            \"UGT8\",\n            \"FA2H\"\n          ]\n        },\n        {\n          \"name\": \"Oligodendrocyte progenitor differentiation\",\n          \"citations\": [\n            {\n              \"source_id\": \"15\",\n              \"notes\": \"OLIG2 recruits SETDB1 for transcriptional repression, required for OPC differentiation and myelinogenesis\"\n            },\n            {\n              \"source_id\": \"24\",\n              \"notes\": \"GPR17 opposes oligodendrocyte maturation, acts as cell-intrinsic timer of myelination\"\n            }\n          ],\n          \"genes\": [\n            \"SOX6\",\n            \"GPR17\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Myelin sheath structure\",\n          \"citations\": [\n            {\n              \"source_id\": \"49\",\n              \"notes\": \"MOG is adhesion molecule providing structural integrity to myelin sheath\"\n            }\n          ],\n          \"genes\": [\n            \"MOG\",\n            \"CLDN11\",\n            \"LAMB4\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Dysregulated recapitulation of developmental oligodendrocyte specification in infiltrative tumor regions\",\n        \"Aberrant myelin lipid synthesis contributing to altered membrane composition and metabolic dependence\",\n        \"Enhanced stemness and reduced differentiation commitment in infiltrative GBM cells\",\n        \"Potential metabolic reprogramming toward lipid synthesis over classic oligodendrocyte functions\"\n      ],\n      \"evidence_summary\": \"Multiple genes in this program (MYRF, MOG, SOX6, UGT8, GPR17, CLDN11) are well-established as core regulators of oligodendrocyte differentiation and myelin maintenance. Recent spatial transcriptomics studies show that peritumoral GBM cells adopt oligodendrocyte progenitor cell (OPC)-like states with increased expression of developmental genes including those in this program. The program is particularly relevant to GBM because infiltrative cells show epigenetic signatures mirroring developing OPCs, suggesting neurodevelopmental hijacking of this developmental pathway.\",\n      \"significance_score\": 0.92,\n      \"citations\": [\n        {\n          \"source_id\": \"1\",\n          \"notes\": \"Spatial transcriptomics reveals OPC-like malignant states in infiltrated brain tissue\"\n        },\n        {\n          \"source_id\": \"5\",\n          \"notes\": \"Peritumoral GBM cells have epigenetic encoding mirroring uncommitted developing OPCs\"\n        },\n        {\n          \"source_id\": \"15\",\n          \"notes\": \"OLIG2-SETDB1 complex essential for OPC differentiation and myelination\"\n        },\n        {\n          \"source_id\": \"24\",\n          \"notes\": \"GPR17 acts as intrinsic timer of myelination through ID protein regulation\"\n        },\n        {\n          \"source_id\": \"25\",\n          \"notes\": \"MYRF and SOX10 compose feedback regulatory loops for myelin development\"\n        },\n        {\n          \"source_id\": \"27\",\n          \"notes\": \"UGT8 catalyzes key myelin lipid synthesis step\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"MYRF\",\n        \"MOG\",\n        \"OMG\",\n        \"BCAS1\",\n        \"CLDN11\",\n        \"UGT8\",\n        \"FA2H\",\n        \"SOX6\",\n        \"GPR17\",\n        \"LAMB4\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"SOX10\",\n          \"OLIG2\",\n          \"PDGFRA\",\n          \"MBP\",\n          \"PLP\",\n          \"CNP\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"15\",\n            \"notes\": \"SOX10 and OLIG2 are master regulators that activate myelin gene networks\"\n          },\n          {\n            \"source_id\": \"25\",\n            \"notes\": \"MYRF-SOX10 feedback loop essential for myelin maintenance\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Notch signaling and neural stem cell maintenance\",\n      \"description\": \"The Notch pathway acts as a critical regulator of neural progenitor self-renewal and inhibition of differentiation in developing CNS. In GBM, elevated Notch signaling through ligands DLL1 and DLL3 maintains cancer stem cell properties and is particularly enriched in infiltrative tumor regions. This program operates downstream of ASCL1 and OLIG2, which are co-expressed transcriptional regulators that determine cellular plasticity and lineage specification in GBM.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Notch ligand-receptor interactions\",\n          \"citations\": [\n            {\n              \"source_id\": \"1\",\n              \"notes\": \"Delta-like ligands (DLL1, DLL3) upregulated in infiltrated regions, associated with NPC-like states\"\n            },\n            {\n              \"source_id\": \"13\",\n              \"notes\": \"DLL1 activation of Notch1 maintains stem cell phenotype of glioma initiating cells\"\n            },\n            {\n              \"source_id\": \"16\",\n              \"notes\": \"DLL1 most upregulated gene in infiltrated brain tissue; NPC-like marker\"\n            }\n          ],\n          \"genes\": [\n            \"DLL1\",\n            \"DLL3\"\n          ]\n        },\n        {\n          \"name\": \"Stemness and self-renewal maintenance\",\n          \"citations\": [\n            {\n              \"source_id\": \"2\",\n              \"notes\": \"ASCL1 and OLIG2 mark apex of GBM cellular hierarchy, determine NSC/astrocyte-like and OPC-like states\"\n            },\n            {\n              \"source_id\": \"13\",\n              \"notes\": \"Notch signaling maintains glioma stem cell self-renewal and inhibits differentiation\"\n            },\n            {\n              \"source_id\": \"45\",\n              \"notes\": \"LIN28B represses let-7 miRNAs, maintaining stem cell programs and pluripotency factors\"\n            }\n          ],\n          \"genes\": [\n            \"LIN28B\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [],\n      \"predicted_cellular_impact\": [\n        \"Enhanced maintenance of tumor-initiating cell populations with stem-like properties\",\n        \"Resistance to differentiation cues and reduced lineage commitment\",\n        \"Increased self-renewal capacity enabling recurrence and treatment resistance\",\n        \"Spatial enrichment in infiltrative regions promoting brain invasion\",\n        \"Activation of growth factor receptor pathways (EGFR, FGFR) downstream of Notch\"\n      ],\n      \"evidence_summary\": \"DLL1 and DLL3 are well-established Notch ligands that are specifically upregulated in infiltrative GBM regions compared to tumor core. Multiple studies show that higher Notch signaling correlates with worse prognosis and maintains glioma stem cell phenotype. LIN28B functions to repress the tumor-suppressive let-7 miRNA family, thereby maintaining expression of oncogenic factors like MYC and allowing sustained stemness. The program is particularly relevant in GBM because Notch signaling marks the transition from core to infiltrative tumor regions and promotes the acquisition of progenitor-like states.\",\n      \"significance_score\": 0.88,\n      \"citations\": [\n        {\n          \"source_id\": \"1\",\n          \"notes\": \"Spatial transcriptomics shows DLL1/DLL3 enriched in NPC-like states of infiltrated tissue\"\n        },\n        {\n          \"source_id\": \"2\",\n          \"notes\": \"ASCL1 and OLIG2 control Notch pathway and determine GBM cell type specification\"\n        },\n        {\n          \"source_id\": \"13\",\n          \"notes\": \"Comprehensive review of Notch signaling in GBM pathogenesis and stem cell maintenance\"\n        },\n        {\n          \"source_id\": \"16\",\n          \"notes\": \"DLL1 is leading gene upregulated in infiltrated regions, marks NPC-like malignant state\"\n        },\n        {\n          \"source_id\": \"45\",\n          \"notes\": \"LIN28-let-7 axis regulates stem cell self-renewal versus differentiation decision\"\n        },\n        {\n          \"source_id\": \"48\",\n          \"notes\": \"LIN28AB drives cancer stem cell maintenance through let-7 repression\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"DLL1\",\n        \"DLL3\",\n        \"LIN28B\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"NOTCH1\",\n          \"NOTCH3\",\n          \"NOTCH4\",\n          \"HES1\",\n          \"HEY1\",\n          \"MAML1\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"13\",\n            \"notes\": \"NOTCH1, NOTCH3, NOTCH4 are key receptors; HES1 and HEY1 are downstream effectors\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Synaptic adhesion and neuronal crosstalk\",\n      \"description\": \"GBM cells establish bidirectional communication with neurons through synaptic adhesion molecules and neurotrophic factors. This program includes cell adhesion molecules (ALCAM, LRRC7, MDGA2), guidance molecules (SLIT1, SEMA3E), and neuropeptide receptors (TACR1) that mediate neuron-tumor interactions. Active neuronal activity promotes GBM proliferation through secretion of factors including neuroligin-3 (NLGN3) and activation of growth factor pathways, establishing a tumor microenvironment permissive for GBM growth.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Synaptic protein interactions\",\n          \"citations\": [\n            {\n              \"source_id\": \"43\",\n              \"notes\": \"NLGN3 secreted by active neurons promotes HGG proliferation; sufficient and necessary for mitogenic effect\"\n            },\n            {\n              \"source_id\": \"46\",\n              \"notes\": \"NLGN3 levels higher in cortex; correlates with GBM recurrence in deep brain regions\"\n            }\n          ],\n          \"genes\": [\n            \"LRRC7\",\n            \"ALCAM\",\n            \"MDGA2\",\n            \"LRRC3B\"\n          ]\n        },\n        {\n          \"name\": \"Axon guidance and neuronal repulsion\",\n          \"citations\": [\n            {\n              \"source_id\": \"33\",\n              \"notes\": \"Slit proteins (including SLIT1) inhibit leukocyte and potentially cancer cell migration through Robo receptors\"\n            },\n            {\n              \"source_id\": \"36\",\n              \"notes\": \"Slit-Robo signaling pathway regulates nervous system development and cell migration\"\n            }\n          ],\n          \"genes\": [\n            \"SLIT1\",\n            \"SEMA3E\",\n            \"KIF21B\"\n          ]\n        },\n        {\n          \"name\": \"Neuropeptide signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"57\",\n              \"notes\": \"TACR1 (tachykinin receptor) stimulates NF-kappaB activation and proinflammatory gene expression\"\n            },\n            {\n              \"source_id\": \"60\",\n              \"notes\": \"Tachykinins and their receptors contribute to physiological control and disease mechanisms\"\n            }\n          ],\n          \"genes\": [\n            \"TACR1\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Perineuronal extracellular matrix\",\n          \"citations\": [\n            {\n              \"source_id\": \"51\",\n              \"notes\": \"TNR (Tenascin-R) endocytosed and recycled near synapses, activity-dependent cycling\"\n            },\n            {\n              \"source_id\": \"54\",\n              \"notes\": \"ECM protein recycling critical for maintaining synaptic function\"\n            }\n          ],\n          \"genes\": [\n            \"TNR\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced responsiveness to neuronal activity-dependent paracrine signals\",\n        \"Increased proliferation in cortical regions with high neuronal density\",\n        \"Spatial preference for infiltration toward neurons with high synaptic activity\",\n        \"Establishment of stable neuron-tumor synaptic contacts promoting tumor growth\",\n        \"Activation of growth factor signaling cascades (PI3K-mTOR) downstream of neuronal ligands\",\n        \"GBM recurrence in deep brain structures with lower synaptic density but localized neuronal hyperactivity\"\n      ],\n      \"evidence_summary\": \"Active neurons promote GBM growth through secretion of the synaptic protein neuroligin-3 (NLGN3), which activates PI3K-mTOR signaling in tumor cells. NLGN3 expression in human GBM negatively correlates with patient survival. Multiple synaptic adhesion molecules (LRRC7, ALCAM, MDGA2) are involved in formation and maintenance of neuronal circuits and are likely repurposed by tumor cells to establish tumor-neuron contacts. SLIT1 and SEMA3E are axon guidance molecules that may control tumor cell migration relative to neuronal processes. This program is particularly significant in GBM because it explains the spatial patterning of tumor growth relative to neuronal density and the dependence of infiltrative GBM on neuronal stimulation.\",\n      \"significance_score\": 0.85,\n      \"citations\": [\n        {\n          \"source_id\": \"1\",\n          \"notes\": \"Spatial transcriptomics reveals increased synaptic gene expression in infiltrated regions\"\n        },\n        {\n          \"source_id\": \"5\",\n          \"notes\": \"Peritumoral GBM cells colocalize with neurons; increased synaptic activity and NOTCH signaling\"\n        },\n        {\n          \"source_id\": \"43\",\n          \"notes\": \"Definitive demonstration that active neurons promote HGG proliferation through NLGN3 secretion\"\n        },\n        {\n          \"source_id\": \"46\",\n          \"notes\": \"NLGN3 correlates with GBM recurrence patterns; higher in cortex than deep brain in normal state\"\n        },\n        {\n          \"source_id\": \"4\",\n          \"notes\": \"NLGN-NRXN interactions identified as potential therapeutic targets in glioma\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"LRRC7\",\n        \"ALCAM\",\n        \"MDGA2\",\n        \"SLIT1\",\n        \"SEMA3E\",\n        \"KIF21B\",\n        \"TACR1\",\n        \"TNR\",\n        \"LRRC3B\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"NLGN1\",\n          \"NLGN3\",\n          \"NRXN1\",\n          \"NRXN2\",\n          \"NRXN3\",\n          \"ROBO1\",\n          \"ROBO2\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"43\",\n            \"notes\": \"NLGN3 is primary mitogen; neuroligins interact with neurexins\"\n          },\n          {\n            \"source_id\": \"33\",\n            \"notes\": \"ROBO1 and ROBO2 are receptors for Slit-mediated migration inhibition\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Ion homeostasis and osmotic cell volume regulation\",\n      \"description\": \"GBM cells rely on ion channels and water transporters to regulate intracellular osmolarity and cell volume during migration through confined brain parenchyma and at leading edge of invasion. This program includes aquaporins (AQP4), cation channels (ANO3, ANO4, TRPC4, CACNA1E), anion channels, and ion exchangers (SLC8A3, SLC5A4, SLC26A7). Proper ion homeostasis is essential for lamellipodial dynamics, cell shape changes, and migration through narrow extracellular spaces.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Water channel-mediated osmotic water transport\",\n          \"citations\": [\n            {\n              \"source_id\": \"55\",\n              \"notes\": \"AQP4 upregulated in GBM; involved in edema formation and cell migration\"\n            },\n            {\n              \"source_id\": \"58\",\n              \"notes\": \"AQP4 localizes to lamellipodia; facilitates water influx during cell migration\"\n            }\n          ],\n          \"genes\": [\n            \"AQP4\"\n          ]\n        },\n        {\n          \"name\": \"Calcium-dependent channel activity\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"ANO3 mutations disrupt calcium-dependent signaling; calcium pool abnormalities\"\n            },\n            {\n              \"source_id\": \"12\",\n              \"notes\": \"ANO4 functions as Ca2+-dependent non-selective cation channel\"\n            }\n          ],\n          \"genes\": [\n            \"ANO3\",\n            \"ANO4\",\n            \"CACNA1E\",\n            \"TRPC4\"\n          ]\n        },\n        {\n          \"name\": \"Ion exchange and transport\",\n          \"citations\": [\n            {\n              \"source_id\": \"58\",\n              \"notes\": \"KCl-water extrusion at lamellipodia enhances cell invasion; involves chloride and potassium channels\"\n            }\n          ],\n          \"genes\": [\n            \"SLC8A3\",\n            \"SLC5A4\",\n            \"SLC26A7\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Leading edge membrane dynamics\",\n          \"citations\": [\n            {\n              \"source_id\": \"58\",\n              \"notes\": \"AQP4 polarizes to lamellipodia; increases number and size of lamellipodia in migrating cells\"\n            }\n          ],\n          \"genes\": [\n            \"AQP4\",\n            \"ANO3\",\n            \"ANO4\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced cell volume changes enabling invasion through narrow extracellular spaces\",\n        \"Rapid osmotic adjustment at tumor cell leading edge during migration\",\n        \"Dysregulated calcium signaling supporting proliferation and migration\",\n        \"Contribution to GBM-associated cerebral edema through altered water transport\",\n        \"Reduced migratory capacity if ion channel function is impaired\",\n        \"Calcium dysregulation potentially driving metabolic reprogramming\"\n      ],\n      \"evidence_summary\": \"AQP4 is the water channel with highest flux capacity in brain and is strongly upregulated and redistributed across GBM cell surfaces. Multiple studies demonstrate that AQP4 localizes to lamellipodia and is required for efficient cell migration through narrow spaces. Ion channels are essential for osmotic balance during cell volume changes that accompany migration and invasion. ANO3 and ANO4 are calcium-activated channels; dysregulation of calcium signaling through these channels contributes to abnormal proliferation and migration. The program is critical for GBM because cell migration through dense brain tissue requires precise osmotic control and ion homeostasis.\",\n      \"significance_score\": 0.82,\n      \"citations\": [\n        {\n          \"source_id\": \"55\",\n          \"notes\": \"AQP4 loss in astrocytes alters GBM edema formation and immune microenvironment\"\n        },\n        {\n          \"source_id\": \"58\",\n          \"notes\": \"Comprehensive review of AQP4 roles in glioma migration and invasion\"\n        },\n        {\n          \"source_id\": \"9\",\n          \"notes\": \"ANO3 mutations demonstrate importance of calcium-dependent channel function\"\n        },\n        {\n          \"source_id\": \"12\",\n          \"notes\": \"ANO4 molecular characterization as calcium-activated cation channel\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"AQP4\",\n        \"ANO3\",\n        \"ANO4\",\n        \"CACNA1E\",\n        \"TRPC4\",\n        \"SLC8A3\",\n        \"SLC5A4\",\n        \"SLC26A7\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"KCNC1\",\n          \"KCNC2\",\n          \"CLCN3\",\n          \"CLCN7\",\n          \"CLC2\",\n          \"KCC1\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"58\",\n            \"notes\": \"Ion channels and chloride transporters essential for osmotic gradient that drives water movement\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Cell cycle progression and proliferation\",\n      \"description\": \"Cell cycle regulation in GBM is controlled by cyclin-CDK complexes, with cyclin D1 (CCND1) being a proto-oncogene frequently dysregulated in GBM. CCND1 drives progression from G1 to S phase by phosphorylating retinoblastoma protein (pRb). CDCA7L (cell division cycle-associated 7 like) is a c-MYC target that promotes proliferation by upregulating CCND1. Elevated cyclin D1 is associated with poor prognosis, enhanced invasiveness, and reduced apoptosis in GBM.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"G1/S phase transition\",\n          \"citations\": [\n            {\n              \"source_id\": \"37\",\n              \"notes\": \"Cyclin D1 knockdown inhibits proliferation, induces apoptosis, attenuates invasion of GBM cells\"\n            },\n            {\n              \"source_id\": \"40\",\n              \"notes\": \"CDCA7L targets CCND1; knockdown arrests cells at G0/G1 phase\"\n            }\n          ],\n          \"genes\": [\n            \"CCND1\"\n          ]\n        },\n        {\n          \"name\": \"Proliferation regulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"40\",\n              \"notes\": \"CDCA7L is c-MYC target gene; promotes proliferation through CCND1 regulation\"\n            }\n          ],\n          \"genes\": [\n            \"CDCA7L\"\n          ]\n        },\n        {\n          \"name\": \"Apoptosis resistance\",\n          \"citations\": [\n            {\n              \"source_id\": \"37\",\n              \"notes\": \"Cyclin D1 overexpression increases MDR1 and Bcl-2 expression while decreasing caspase-3\"\n            }\n          ],\n          \"genes\": [\n            \"CCND1\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [],\n      \"predicted_cellular_impact\": [\n        \"Accelerated progression through G1/S checkpoint in GBM cells\",\n        \"Enhanced proliferative capacity and increased tumor growth rate\",\n        \"Increased drug resistance through upregulation of multidrug resistance proteins\",\n        \"Reduced apoptotic sensitivity to pro-death signals\",\n        \"Contribution to poor clinical prognosis and shorter survival\"\n      ],\n      \"evidence_summary\": \"CCND1 (cyclin D1) is one of the most frequently dysregulated genes in GBM. Cyclin D1 drives cell cycle progression by forming active complexes with CDK4/6 that phosphorylate pRb, releasing E2F transcription factors. High CCND1 expression correlates with poor prognosis and is associated with enhanced invasiveness and resistance to apoptosis. CDCA7L is a MYC-regulated target that promotes proliferation through CCND1 upregulation. The program is relevant to GBM because GBM cells exhibit constitutive hyperproliferation even in non-permissive microenvironments.\",\n      \"significance_score\": 0.78,\n      \"citations\": [\n        {\n          \"source_id\": \"37\",\n          \"notes\": \"Comprehensive study of cyclin D1 function in GBM proliferation, apoptosis, and invasion\"\n        },\n        {\n          \"source_id\": \"40\",\n          \"notes\": \"CDCA7L-CCND1 axis demonstrated in GBM; knockdown inhibits proliferation\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"CCND1\",\n        \"CDCA7L\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"CDK4\",\n          \"CDK6\",\n          \"RB1\",\n          \"E2F1\",\n          \"MYC\",\n          \"p21\",\n          \"p27\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"40\",\n            \"notes\": \"CCND1 functions through CDK4/6 to phosphorylate Rb and drive proliferation\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Extracellular matrix remodeling and vasculature assembly\",\n      \"description\": \"The GBM tumor microenvironment is characterized by extensive extracellular matrix (ECM) remodeling and abnormal vasculature. Collagen types I, IV, and XX are abundant in GBM and contribute to tumor stiffness, invasion, and vascular abnormalities. This program includes fibrillar collagens (COL4A3, COL4A4, COL20A1), basement membrane components (LAMB4), ECM glycoproteins (TNR, THSD4), and ECM remodeling enzymes (ADAMTS17, HS6ST2). ECM composition and organization influence cell migration, vascular permeability, and therapeutic resistance.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Type IV collagen biosynthesis and basement membrane assembly\",\n          \"citations\": [\n            {\n              \"source_id\": \"19\",\n              \"notes\": \"Collagen type IV is major basement membrane component; distribution changes with glioma grade\"\n            },\n            {\n              \"source_id\": \"22\",\n              \"notes\": \"COL4A1-2 expression increases with glioma progression; marks high-grade tumors\"\n            }\n          ],\n          \"genes\": [\n            \"COL4A3\",\n            \"COL4A4\"\n          ]\n        },\n        {\n          \"name\": \"Fibrillar collagen deposition\",\n          \"citations\": [\n            {\n              \"source_id\": \"19\",\n              \"notes\": \"Collagen clustering identifies distinct tumor microenvironments associated with genetic features\"\n            }\n          ],\n          \"genes\": [\n            \"COL20A1\"\n          ]\n        },\n        {\n          \"name\": \"ECM glycoprotein organization\",\n          \"citations\": [\n            {\n              \"source_id\": \"51\",\n              \"notes\": \"TNR endocytosed and recycled near synapses in activity-dependent manner; essential for neuronal function\"\n            }\n          ],\n          \"genes\": [\n            \"TNR\"\n          ]\n        },\n        {\n          \"name\": \"ECM proteolysis and remodeling\",\n          \"citations\": [\n            {\n              \"source_id\": \"19\",\n              \"notes\": \"ADAMTS proteases remodel ECM; associated with tumor progression\"\n            }\n          ],\n          \"genes\": [\n            \"ADAMTS17\",\n            \"HS6ST2\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Basement membrane\",\n          \"citations\": [\n            {\n              \"source_id\": \"22\",\n              \"notes\": \"Type IV collagen primary component of basement membrane; critical for BBB function in normal brain\"\n            }\n          ],\n          \"genes\": [\n            \"COL4A3\",\n            \"COL4A4\",\n            \"LAMB4\"\n          ]\n        },\n        {\n          \"name\": \"Vascular matrix\",\n          \"citations\": [\n            {\n              \"source_id\": \"1\",\n              \"notes\": \"MGP and TIMP1 expressed in microvascular proliferation areas; associated with mesenchymal state\"\n            }\n          ],\n          \"genes\": [\n            \"COL20A1\",\n            \"TNR\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Increased tumor microenvironmental stiffness promoting invasive phenotype\",\n        \"Enhanced vascular permeability and edema formation\",\n        \"Creation of hypoxic niches through altered ECM organization and vascular abnormalities\",\n        \"Promotion of mesenchymal GBM state in regions with elevated collagen\",\n        \"Reduced drug penetration due to ECM barrier function\",\n        \"Enhanced cell migration through ECM-rich regions\"\n      ],\n      \"evidence_summary\": \"Type IV collagen (COL4A) expression is markedly increased in GBM compared to normal brain and correlates with grade and malignancy. Multiple spatial transcriptomics and bulk sequencing studies show collagen clustering associated with distinct tumor phenotypes and genetic alterations. TNR is an ECM glycoprotein enriched in perineuronal nets and perisynaptic ECM that undergoes activity-dependent recycling. ADAMTS17 and HS6ST2 participate in ECM remodeling. The program is highly relevant to GBM because ECM composition is a critical determinant of tumor fate, influencing both cell phenotype and therapeutic response.\",\n      \"significance_score\": 0.80,\n      \"citations\": [\n        {\n          \"source_id\": \"1\",\n          \"notes\": \"Spatial transcriptomics identifies collagen-related genes in tumor core and MVP regions\"\n        },\n        {\n          \"source_id\": \"19\",\n          \"notes\": \"Large-scale analysis showing collagens predict genetic features and patient outcomes\"\n        },\n        {\n          \"source_id\": \"22\",\n          \"notes\": \"COL4A family analysis reveals prognostic significance in GBM and LGG\"\n        },\n        {\n          \"source_id\": \"51\",\n          \"notes\": \"Tenascin-R ECM protein recycling mechanism maintains synaptic function\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"COL4A3\",\n        \"COL4A4\",\n        \"COL20A1\",\n        \"LAMB4\",\n        \"TNR\",\n        \"ADAMTS17\",\n        \"HS6ST2\",\n        \"THSD4\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"COL4A1\",\n          \"COL4A2\",\n          \"COL1A1\",\n          \"COL1A2\",\n          \"TIMP1\",\n          \"MMP2\",\n          \"MMP9\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"22\",\n            \"notes\": \"COL4A1-2 are major collagen IV components; TIMP1 is key ECM regulator\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Integrin-mediated cell adhesion and migration\",\n      \"description\": \"Cell migration and invasion in GBM are fundamentally dependent on integrin-ECM interactions that link the extracellular matrix to the actin cytoskeleton. Integrins like ITGA9 (α9β1 heterodimer) interact with ECM components including thrombospondin, fibronectin, and VEGF isoforms. FERMT1 (fermitin family homolog 1, also called kindlin-1) is a FERM-domain protein that binds integrin cytoplasmic tails and cooperates with talin to activate integrins. This program coordinates cell adhesion dynamics with cell-matrix signaling to enable migration.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Integrin activation and adhesion\",\n          \"citations\": [\n            {\n              \"source_id\": \"8\",\n              \"notes\": \"FERMT1 (kindlin-1) binds integrin β1 and β3 cytoplasmic tails; contributes to integrin activation\"\n            },\n            {\n              \"source_id\": \"11\",\n              \"notes\": \"FERMT1 involved in cell adhesion; contributes to integrin activation when coexpressed with talin\"\n            }\n          ],\n          \"genes\": [\n            \"FERMT1\",\n            \"ITGA9\"\n          ]\n        },\n        {\n          \"name\": \"Cell-matrix interaction signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"50\",\n              \"notes\": \"ITGA9 facilitates accelerated cell migration; regulates angiogenesis, lymphangiogenesis, and cancer cell proliferation\"\n            }\n          ],\n          \"genes\": [\n            \"ITGA9\"\n          ]\n        },\n        {\n          \"name\": \"Focal adhesion dynamics\",\n          \"citations\": [\n            {\n              \"source_id\": \"8\",\n              \"notes\": \"FERMT1 colocalizes with vinculin and paxillin at focal adhesions in keratinocytes\"\n            }\n          ],\n          \"genes\": [\n            \"FERMT1\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Focal adhesions\",\n          \"citations\": [\n            {\n              \"source_id\": \"8\",\n              \"notes\": \"FERMT1 associates with focal adhesion proteins; loss causes disrupted adhesion and migration\"\n            }\n          ],\n          \"genes\": [\n            \"FERMT1\",\n            \"ITGA9\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced cell-matrix adhesion enabling stable interactions with ECM during migration\",\n        \"Increased integrin signaling (β1/β3) promoting proliferation and survival\",\n        \"Rapid adhesion turnover allowing efficient migration through tissue\",\n        \"Sustained migratory phenotype through integrin-dependent signaling\",\n        \"Modulation of cell morphology and actin dynamics at leading edge\"\n      ],\n      \"evidence_summary\": \"Integrin α9β1 is known to regulate cell migration and is involved in angiogenesis and lymphangiogenesis. FERMT1 (kindlin-1) is a critical regulator of integrin activation that binds to integrin cytoplasmic tails and cooperates with talin. Loss of FERMT1 results in reduced integrin activation and impaired cell adhesion and migration. In GBM context, integrin-ECM interactions are essential for tumor cell migration through brain parenchyma and invasion into surrounding tissue.\",\n      \"significance_score\": 0.75,\n      \"citations\": [\n        {\n          \"source_id\": \"8\",\n          \"notes\": \"FERMT1 loss-of-function causes integrin dysfunction and migration defects\"\n        },\n        {\n          \"source_id\": \"50\",\n          \"notes\": \"ITGA9 epigenetic silencing in breast cancer; hypermethylation reduces expression\"\n        },\n        {\n          \"source_id\": \"51\",\n          \"notes\": \"Integrins critical for ECM remodeling and neuronal function\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"ITGA9\",\n        \"FERMT1\",\n        \"ALCAM\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"TALIN1\",\n          \"TALIN2\",\n          \"PARVIN\",\n          \"FAK\",\n          \"SRC\",\n          \"ACTN\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"8\",\n            \"notes\": \"FERMT1 cooperates with talin to activate integrins; FAK and SRC are downstream integrin signaling kinases\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Lipid metabolism and myelin-derived nutrient scavenging\",\n      \"description\": \"GBM, particularly mesenchymal-like (MES) GBM cells, exhibit altered lipid metabolism that enables them to utilize myelin-derived lipids from the tumor microenvironment. Lipid-laden macrophages (LLMs) internalize myelin debris and transfer cholesterol and fatty acids to GBM cells through metabolic symbiosis. This program involves lipid biosynthetic enzymes (PLA2G4A, PLPP4, PLAAT1, DGKB, FA2H) that remodel lipids for membrane synthesis and metabolic signaling. The liver X receptor (LXR) pathway activates macrophage myelin uptake, creating a tumor-macrophage metabolic axis.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Phospholipid metabolism and remodeling\",\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"LLMs transfer lipids (cholesterol, phospholipids) from myelin to MES-like GBM cells in LXR/ABCA1-dependent manner\"\n            }\n          ],\n          \"genes\": [\n            \"PLA2G4A\",\n            \"PLPP4\",\n            \"PLAAT1\",\n            \"DGKB\"\n          ]\n        },\n        {\n          \"name\": \"Fatty acid and sphingolipid metabolism\",\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"Myelin recycling pathway: LLMs phagocytose myelin, accumulate lipids as droplets; transfer to GBM cells\"\n            }\n          ],\n          \"genes\": [\n            \"FA2H\",\n            \"UGT8\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [],\n      \"predicted_cellular_impact\": [\n        \"Enhanced membrane biosynthesis supporting rapid proliferation\",\n        \"Utilization of exogenous myelin lipids reducing dependence on de novo lipogenesis\",\n        \"Altered signaling lipid composition modulating proliferation and survival pathways\",\n        \"Metabolic symbiosis between MES-like GBM cells and lipid-laden macrophages\",\n        \"Reduced oxidative stress through lipid remodeling\",\n        \"Enhanced mesenchymal phenotype and invasiveness\"\n      ],\n      \"evidence_summary\": \"Recent studies identify a remarkable metabolic symbiosis between glioblastoma cells and tumor-associated macrophages. Lipid-laden macrophages (LLMs), enriched with GPNMB expression, preferentially interact with mesenchymal-like (MES) GBM cells. LLMs are epigenetically rewired to internalize myelin debris through LXR pathway activation. The myelin-derived cholesterol is transferred to GBM cells where it is incorporated into phospholipids for membrane synthesis, fueling mesenchymal GBM progression. This program represents a critical metabolic adaptation that explains how GBM cells sustain rapid proliferation in lipid-rich but nutrient-poor brain microenvironment.\",\n      \"significance_score\": 0.76,\n      \"citations\": [\n        {\n          \"source_id\": \"3\",\n          \"notes\": \"Comprehensive study of lipid-laden macrophages, myelin recycling, and tumor-macrophage metabolic symbiosis\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"PLA2G4A\",\n        \"PLPP4\",\n        \"PLAAT1\",\n        \"DGKB\",\n        \"FA2H\",\n        \"UGT8\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"LXR\",\n          \"ABCA1\",\n          \"GPNMB\",\n          \"SREBP\",\n          \"FASN\",\n          \"ACC\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"3\",\n            \"notes\": \"LXR activation is key upstream regulator of LLM lipid uptake; ABCA1 transfers lipids\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Growth factor receptor signaling networks\",\n      \"description\": \"GBM cells exhibit dysregulation of multiple growth factor receptor pathways including EGFR, FGF receptors, and ErbB receptors that drive proliferation, survival, and migration. FGF12 is an intracellular FGF homologous factor (FHF) that modulates intracellular signaling. ERBB3 (HER3) is a neuregulin receptor that heterodimerizes with other ErbB family members to activate PI3K-AKT-mTOR and MAPK pathways. VIPR2 is a G-protein coupled receptor for vasoactive intestinal peptide (VIP) that activates cAMP signaling. These receptors converge on mTOR, AKT, and ERK pathways to promote tumor cell proliferation.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"ErbB receptor heterodimerization and activation\",\n          \"citations\": [\n            {\n              \"source_id\": \"32\",\n              \"notes\": \"ERBB3 expressed in CD133+ putative cancer stem cells; potential novel therapeutic target\"\n            },\n            {\n              \"source_id\": \"35\",\n              \"notes\": \"Neuregulin (NRG1)-ErbB signaling regulates myelination and neural development\"\n            }\n          ],\n          \"genes\": [\n            \"ERBB3\"\n          ]\n        },\n        {\n          \"name\": \"FGF signaling and pathway activation\",\n          \"citations\": [\n            {\n              \"source_id\": \"39\",\n              \"notes\": \"FGF signaling regulates cell proliferation, differentiation, and migration in CNS development\"\n            },\n            {\n              \"source_id\": \"42\",\n              \"notes\": \"FGF/FGFR signaling dysregulation implicated in cancer progression\"\n            }\n          ],\n          \"genes\": [\n            \"FGF12\"\n          ]\n        },\n        {\n          \"name\": \"G-protein coupled receptor signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"23\",\n              \"notes\": \"CALCRL (CGRP receptor) signaling involves G-protein coupling and cAMP activation\"\n            }\n          ],\n          \"genes\": [\n            \"VIPR2\",\n            \"CALCRL\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [],\n      \"predicted_cellular_impact\": [\n        \"Enhanced PI3K-AKT-mTOR signaling promoting anabolic metabolism and proliferation\",\n        \"Sustained MAPK-ERK activation driving proliferation and survival\",\n        \"Increased genomic instability through aberrant growth factor signaling\",\n        \"Cross-talk between multiple growth factor pathways creating redundancy and therapeutic resistance\",\n        \"Amplification of early response genes and cell cycle progression\"\n      ],\n      \"evidence_summary\": \"Growth factor receptor dysregulation is a hallmark of GBM. ERBB3 (HER3) is expressed in a subset of CD133+ putative cancer stem cells and represents a potential therapeutic target. ErbB receptors signal through multiple pathways including PI3K-AKT and MAPK-ERK to promote proliferation and survival. FGF signaling is involved in neural development and can be dysregulated in GBM. VIPR2 (VIP receptor) and CALCRL couple to G proteins to activate cAMP signaling. The convergence of multiple growth factor pathways on common downstream effectors (mTOR, AKT, ERK) creates pathway redundancy that contributes to therapeutic resistance.\",\n      \"significance_score\": 0.72,\n      \"citations\": [\n        {\n          \"source_id\": \"32\",\n          \"notes\": \"ERBB3 expression in CD133+ cancer stem cells; distinct from EGFR distribution\"\n        },\n        {\n          \"source_id\": \"35\",\n          \"notes\": \"Neuregulin-ERBB signaling in nervous system development and myelination\"\n        },\n        {\n          \"source_id\": \"39\",\n          \"notes\": \"FGF signaling in CNS development and organogenesis\"\n        },\n        {\n          \"source_id\": \"42\",\n          \"notes\": \"FGF/FGFR pathway in organ development and disease including cancer\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"ERBB3\",\n        \"FGF12\",\n        \"VIPR2\",\n        \"CALCRL\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"EGFR\",\n          \"FGFR1\",\n          \"FGFR2\",\n          \"FGFR3\",\n          \"NRG1\",\n          \"NRG2\",\n          \"VIP\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"32\",\n            \"notes\": \"EGFR amplified in ~40% of GBM; ErbB family shows heterodimerization\"\n          },\n          {\n            \"source_id\": \"42\",\n            \"notes\": \"FGF ligands bind FGFRs; HSPGs serve as cofactors\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Lin28-let-7 axis regulating stemness and differentiation\",\n      \"description\": \"The Lin28-let-7 pathway is a conserved heterochronic regulatory axis that controls the balance between self-renewal and differentiation in stem cells and cancer. LIN28B is an RNA-binding protein that blocks biogenesis of the tumor-suppressive let-7 microRNA family by recruiting Terminal Uridylyl Transferase (ZCCHC11) that polyuridylates and marks pre-let-7 for degradation. By repressing let-7, LIN28B maintains expression of oncogenes including MYC, HMGA2, RAS, and pluripotency factors. This program is particularly relevant in GBM where stemness is associated with treatment resistance and recurrence.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"miRNA biogenesis inhibition and let-7 repression\",\n          \"citations\": [\n            {\n              \"source_id\": \"45\",\n              \"notes\": \"Lin28 inhibits post-transcriptional maturation of let-7 by recruiting TUTase; blocks Dicer loading of pre-let-7\"\n            },\n            {\n              \"source_id\": \"48\",\n              \"notes\": \"LIN28A/B repress all let-7 family members; coordinate downregulation of tumor suppressor miRNAs\"\n            }\n          ],\n          \"genes\": [\n            \"LIN28B\"\n          ]\n        },\n        {\n          \"name\": \"Oncogene maintenance through let-7 repression\",\n          \"citations\": [\n            {\n              \"source_id\": \"45\",\n              \"notes\": \"Let-7 directly represses MYC, HMGA2, RAS, and other oncogenes; LIN28 maintains these via let-7 inhibition\"\n            },\n            {\n              \"source_id\": \"48\",\n              \"notes\": \"LIN28A/B establish positive feedback with C-MYC; MYC upregulates LIN28 expression\"\n            }\n          ],\n          \"genes\": [\n            \"LIN28B\"\n          ]\n        },\n        {\n          \"name\": \"Stem cell self-renewal versus differentiation decision\",\n          \"citations\": [\n            {\n              \"source_id\": \"45\",\n              \"notes\": \"Lin28 and let-7 form highly conserved axis that temporally regulates self-renewal and differentiation\"\n            }\n          ],\n          \"genes\": [\n            \"LIN28B\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [],\n      \"predicted_cellular_impact\": [\n        \"Enhanced and sustained expression of oncogenic transcription factors (MYC, HMGA2)\",\n        \"Maintenance of stemness and resistance to differentiation signals\",\n        \"Increased chemotherapy and radiation resistance\",\n        \"Promotion of epithelial-mesenchymal transition (EMT) phenotype\",\n        \"Enhanced tumor-initiating cell (TIC) properties\",\n        \"Increased metabolic plasticity enabling adaptation to microenvironmental changes\"\n      ],\n      \"evidence_summary\": \"The Lin28-let-7 axis is a fundamental regulator of stemness in both normal development and cancer. LIN28B is frequently upregulated in cancers and is associated with poor prognosis. LIN28B represses let-7 family miRNAs, allowing derepression of oncogenic targets including MYC, HMGA2, and RAS. Let-7 is a tumor-suppressive miRNA that is downregulated in multiple cancer types. In GBM, LIN28B-mediated stemness maintenance is associated with therapeutic resistance and enhanced tumor-initiating capacity. The axis has been shown to regulate both stemness and metabolic reprogramming in cancer stem cells.\",\n      \"significance_score\": 0.78,\n      \"citations\": [\n        {\n          \"source_id\": \"45\",\n          \"notes\": \"Comprehensive review of Lin28-let-7 axis in stem cell biology and cancer\"\n        },\n        {\n          \"source_id\": \"48\",\n          \"notes\": \"LIN28AB drives cancer stem cell maintenance; let-7 acts as barrier to stemness\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"LIN28B\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"LIN28A\",\n          \"ZCCHC11\",\n          \"DICER\",\n          \"DROSHA\",\n          \"DGCR8\",\n          \"MYC\",\n          \"HMGA2\",\n          \"KRAS\",\n          \"LET7A\",\n          \"LET7B\",\n          \"LET7C\",\n          \"LET7D\",\n          \"LET7E\",\n          \"LET7F\",\n          \"LET7G\",\n          \"LET7I\",\n          \"LET7MIR\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"45\",\n            \"notes\": \"LIN28A/B both inhibit let-7 biogenesis; ZCCHC11 recruits polyuridylation; Dicer required for let-7 processing\"\n          },\n          {\n            \"source_id\": \"48\",\n            \"notes\": \"Let-7 directly represses MYC, HMGA2, RAS, and other oncogenic targets\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Developmental transcriptional regulation and cell fate specification\",\n      \"description\": \"GBM cells exhibit striking similarity to embryonic neural progenitor cells and recapitulate developmental gene regulatory networks. This program includes key developmental transcription factors (SOX6, EYA1) and regulatory complexes (EYA1-SIX1-BRG1 BAF) that specify cell fate during neural development. SOX6 is part of the SoxD family and promotes neural progenitor maintenance. EYA1 encodes a dual-function protein with both transcriptional activation and protein phosphatase activity; it interacts with SIX1 and chromatin remodeling complexes to specify sensory and neural cell fates. These factors enable developmental plasticity and undifferentiated phenotype in GBM cells.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Neural progenitor cell maintenance\",\n          \"citations\": [\n            {\n              \"source_id\": \"14\",\n              \"notes\": \"Sox2 and Sox6 form positive feedback loop maintaining neural progenitor cell (NPC) pool\"\n            },\n            {\n              \"source_id\": \"17\",\n              \"notes\": \"SOX5 and SOX6 prevent precocious specification and terminal differentiation of OPCs\"\n            }\n          ],\n          \"genes\": [\n            \"SOX6\"\n          ]\n        },\n        {\n          \"name\": \"Cell fate specification through EYA1-SIX1-BAF complex\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"EYA1 and SIX1 interact with SWI/SNF BAF complex to induce transcriptional programs\"\n            },\n            {\n              \"source_id\": \"34\",\n              \"notes\": \"EYA1-SIX1 complexes specify sensory and neuronal cell fates through chromatin remodeling\"\n            }\n          ],\n          \"genes\": [\n            \"EYA1\"\n          ]\n        },\n        {\n          \"name\": \"Developmental plasticity and lineage commitment\",\n          \"citations\": [\n            {\n              \"source_id\": \"5\",\n              \"notes\": \"Infiltrative GBM cells activate transcriptional programs associated with neurodevelopmental states\"\n            }\n          ],\n          \"genes\": [\n            \"SOX6\",\n            \"EYA1\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [],\n      \"predicted_cellular_impact\": [\n        \"Maintenance of progenitor-like undifferentiated state in GBM cells\",\n        \"Enhanced developmental plasticity enabling adaptation to microenvironmental cues\",\n        \"Activation of neural differentiation programs that are repurposed for invasion\",\n        \"Epigenetic encoding that mirrors developing neural tissue\",\n        \"Sustained expression of stemness-related transcription factors\"\n      ],\n      \"evidence_summary\": \"GBM cells exhibit remarkable similarity to embryonic neural progenitor cells in their transcriptional architecture and epigenetic landscape. SOX6 maintains neural progenitor pools through positive feedback with SOX2 and prevents precocious differentiation. EYA1 functions as a dual-activity protein with intrinsic phosphatase activity and transcriptional activation capacity. EYA1 interacts with SIX1 and the BRG1-BAF chromatin remodeling complex to specify neural and sensory cell fates during development. Recent spatial transcriptomics shows that infiltrative GBM cells in peritumoral regions have epigenetic profiles and transcriptional programs that closely mirror developing OPCs, including increased NOTCH signaling, synaptic genes, and developmental transcription factors.\",\n      \"significance_score\": 0.74,\n      \"citations\": [\n        {\n          \"source_id\": \"5\",\n          \"notes\": \"Infiltrative GBM cells show epigenetic encoding of developing OPCs with increased invasivity and synaptic activity\"\n        },\n        {\n          \"source_id\": \"14\",\n          \"notes\": \"Sox2-Sox6 positive feedback essential for NPC maintenance\"\n        },\n        {\n          \"source_id\": \"17\",\n          \"notes\": \"SoxD proteins (Sox5, Sox6) regulate OPC development and migration\"\n        },\n        {\n          \"source_id\": \"31\",\n          \"notes\": \"EYA1-SIX1 complex in sensory development and organogenesis\"\n        },\n        {\n          \"source_id\": \"34\",\n          \"notes\": \"EYA1 roles in development spanning eye, ear, kidney, and nervous system\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"SOX6\",\n        \"EYA1\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"SOX2\",\n          \"SIX1\",\n          \"SIX5\",\n          \"SMARCA4\",\n          \"BRG1\",\n          \"PAX6\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"14\",\n            \"notes\": \"SOX2 partners with SOX6 in feedback loop; essential for NPC maintenance\"\n          },\n          {\n            \"source_id\": \"34\",\n            \"notes\": \"EYA1 works with SIX1 and chromatin remodeling complexes\"\n          }\n        ]\n      }\n    }\n  ],\n  \"method\": {\n    \"clustering_basis\": [\n      \"Pathway databases and known gene interactions from literature\",\n      \"Spatial transcriptomics studies identifying co-expressed genes in different GBM regions\",\n      \"Functional studies of gene knockdown/overexpression in GBM models\",\n      \"Co-citation analysis linking genes to common biological processes\",\n      \"Integration of normal developmental biology with disease-state dysregulation\"\n    ],\n    \"notes\": \"Gene programs were identified by examining the provided search results for evidence of genes working together in coherent biological processes relevant to GBM. Programs were organized around core biological functions (myelin, Notch signaling, synaptic interactions, ion homeostasis, cell cycle, ECM, adhesion, lipid metabolism, growth factors, stemness, and developmental programs). Each program was validated by evidence that: (1) multiple input genes participate in the same process; (2) the program is relevant to either normal physiology of GBM cell origins or characteristic dysregulations in GBM; (3) multiple independent studies support the gene-program associations; (4) required pathway components are identified, with notation of which are missing from the input list.\"\n  },\n  \"version\": \"1.0\"\n}\n```\n\n## Citations\n\n1. https://pmc.ncbi.nlm.nih.gov/articles/PMC11385527/\n2. https://www.nature.com/articles/s41467-024-54750-9\n3. https://pmc.ncbi.nlm.nih.gov/articles/PMC12165008/\n4. https://www.nature.com/articles/s41588-025-02167-5\n5. https://pubmed.ncbi.nlm.nih.gov/40381621/\n6. https://www.nature.com/articles/s41586-025-09411-2\n7. https://www.pnas.org/doi/10.1073/pnas.0902008106\n8. https://pmc.ncbi.nlm.nih.gov/articles/PMC2751540/\n9. https://pmc.ncbi.nlm.nih.gov/articles/PMC3516598/\n10. https://pmc.ncbi.nlm.nih.gov/articles/PMC2949085/\n11. https://www.uniprot.org/uniprotkb/Q9BQL6/entry\n12. https://www.nature.com/articles/s41598-018-37287-y\n13. https://pmc.ncbi.nlm.nih.gov/articles/PMC6468848/\n14. https://www.pnas.org/doi/10.1073/pnas.1308758111\n15. https://www.nature.com/articles/s41467-022-29068-z\n16. https://www.nature.com/articles/s41467-024-52167-y\n17. https://pubmed.ncbi.nlm.nih.gov/26345464/\n18. https://www.ncbi.nlm.nih.gov/gene/10215\n19. https://www.nature.com/articles/s41525-023-00358-9\n20. https://pmc.ncbi.nlm.nih.gov/articles/PMC11795615/\n21. https://www.nature.com/articles/s41598-018-22452-0\n22. https://pmc.ncbi.nlm.nih.gov/articles/PMC12062008/\n23. https://pubs.acs.org/doi/10.1021/acsptsci.8b00061\n24. https://pubmed.ncbi.nlm.nih.gov/19838178/\n25. https://pmc.ncbi.nlm.nih.gov/articles/PMC8192642/\n26. https://www.neurology.org/doi/10.1212/WNL.0000000000201978\n27. https://maayanlab.cloud/Harmonizome/gene/UGT8\n28. https://en.wikipedia.org/wiki/Myelin_regulatory_factor\n29. https://pubmed.ncbi.nlm.nih.gov/34695769/\n30. https://www.nature.com/articles/6605750\n31. https://pmc.ncbi.nlm.nih.gov/articles/PMC6592036/\n32. https://pmc.ncbi.nlm.nih.gov/articles/PMC3173752/\n33. https://pmc.ncbi.nlm.nih.gov/articles/PMC2072862/\n34. https://portlandpress.com/biochemsoctrans/article/49/3/1397/229138/The-Eyes-Absent-proteins-in-development-and-in\n35. https://pmc.ncbi.nlm.nih.gov/articles/PMC4189115/\n36. https://royalsocietypublishing.org/doi/10.1098/rsob.250026\n37. https://pubmed.ncbi.nlm.nih.gov/21912938/\n38. https://pmc.ncbi.nlm.nih.gov/articles/PMC6773068/\n39. https://pmc.ncbi.nlm.nih.gov/articles/PMC4393358/\n40. https://www.spandidos-publications.com/10.3892/mmr.2019.10349\n41. https://journals.sagepub.com/doi/abs/10.1177/1535759719845324\n42. https://www.nature.com/articles/s41392-020-00222-7\n43. https://pmc.ncbi.nlm.nih.gov/articles/PMC4447122/\n44. https://genesdev.cshlp.org/content/suppl/2006/04/17/gad.381706.DC1/BrackenSuppTable3.pdf\n45. https://pmc.ncbi.nlm.nih.gov/articles/PMC4729067/\n46. https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.1538\n47. https://www.kegg.jp/kegg-bin/get_htext?htext=ko00001.keg&query=myc\n48. https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2017.00031/full\n49. https://en.wikipedia.org/wiki/Myelin_oligodendrocyte_glycoprotein\n50. https://pmc.ncbi.nlm.nih.gov/articles/PMC3218606/\n51. https://www.nature.com/articles/s41467-021-27462-7\n52. https://pubmed.ncbi.nlm.nih.gov/2649509/\n53. https://www.tandfonline.com/doi/abs/10.4161/cam.5.5.17949\n54. https://pubmed.ncbi.nlm.nih.gov/34880248/\n55. https://academic.oup.com/neuro-oncology/article/27/Supplement_5/v462/8319745\n56. https://pmc.ncbi.nlm.nih.gov/articles/PMC11850250/\n57. https://pubmed.ncbi.nlm.nih.gov/17041011/\n58. https://pmc.ncbi.nlm.nih.gov/articles/PMC5458289/\n59. https://www.nature.com/articles/s41523-020-00190-9\n60. https://pmc.ncbi.nlm.nih.gov/articles/PMC3929113/",
    "citations": [
      {
        "source_id": "1",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11385527/"
      },
      {
        "source_id": "2",
        "source_url": "https://www.nature.com/articles/s41467-024-54750-9"
      },
      {
        "source_id": "3",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12165008/"
      },
      {
        "source_id": "4",
        "source_url": "https://www.nature.com/articles/s41588-025-02167-5"
      },
      {
        "source_id": "5",
        "source_url": "https://pubmed.ncbi.nlm.nih.gov/40381621/"
      },
      {
        "source_id": "6",
        "source_url": "https://www.nature.com/articles/s41586-025-09411-2"
      },
      {
        "source_id": "7",
        "source_url": "https://www.pnas.org/doi/10.1073/pnas.0902008106"
      },
      {
        "source_id": "8",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2751540/"
      },
      {
        "source_id": "9",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3516598/"
      },
      {
        "source_id": "10",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2949085/"
      },
      {
        "source_id": "11",
        "source_url": "https://www.uniprot.org/uniprotkb/Q9BQL6/entry"
      },
      {
        "source_id": "12",
        "source_url": "https://www.nature.com/articles/s41598-018-37287-y"
      },
      {
        "source_id": "13",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6468848/"
      },
      {
        "source_id": "14",
        "source_url": "https://www.pnas.org/doi/10.1073/pnas.1308758111"
      },
      {
        "source_id": "15",
        "source_url": "https://www.nature.com/articles/s41467-022-29068-z"
      },
      {
        "source_id": "16",
        "source_url": "https://www.nature.com/articles/s41467-024-52167-y"
      },
      {
        "source_id": "17",
        "source_url": "https://pubmed.ncbi.nlm.nih.gov/26345464/"
      },
      {
        "source_id": "18",
        "source_url": "https://www.ncbi.nlm.nih.gov/gene/10215"
      },
      {
        "source_id": "19",
        "source_url": "https://www.nature.com/articles/s41525-023-00358-9"
      },
      {
        "source_id": "20",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11795615/"
      },
      {
        "source_id": "21",
        "source_url": "https://www.nature.com/articles/s41598-018-22452-0"
      },
      {
        "source_id": "22",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12062008/"
      },
      {
        "source_id": "23",
        "source_url": "https://pubs.acs.org/doi/10.1021/acsptsci.8b00061"
      },
      {
        "source_id": "24",
        "source_url": "https://pubmed.ncbi.nlm.nih.gov/19838178/"
      },
      {
        "source_id": "25",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8192642/"
      },
      {
        "source_id": "26",
        "source_url": "https://www.neurology.org/doi/10.1212/WNL.0000000000201978"
      },
      {
        "source_id": "27",
        "source_url": "https://maayanlab.cloud/Harmonizome/gene/UGT8"
      },
      {
        "source_id": "28",
        "source_url": "https://en.wikipedia.org/wiki/Myelin_regulatory_factor"
      },
      {
        "source_id": "29",
        "source_url": "https://pubmed.ncbi.nlm.nih.gov/34695769/"
      },
      {
        "source_id": "30",
        "source_url": "https://www.nature.com/articles/6605750"
      },
      {
        "source_id": "31",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6592036/"
      },
      {
        "source_id": "32",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3173752/"
      },
      {
        "source_id": "33",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2072862/"
      },
      {
        "source_id": "34",
        "source_url": "https://portlandpress.com/biochemsoctrans/article/49/3/1397/229138/The-Eyes-Absent-proteins-in-development-and-in"
      },
      {
        "source_id": "35",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4189115/"
      },
      {
        "source_id": "36",
        "source_url": "https://royalsocietypublishing.org/doi/10.1098/rsob.250026"
      },
      {
        "source_id": "37",
        "source_url": "https://pubmed.ncbi.nlm.nih.gov/21912938/"
      },
      {
        "source_id": "38",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6773068/"
      },
      {
        "source_id": "39",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4393358/"
      },
      {
        "source_id": "40",
        "source_url": "https://www.spandidos-publications.com/10.3892/mmr.2019.10349"
      },
      {
        "source_id": "41",
        "source_url": "https://journals.sagepub.com/doi/abs/10.1177/1535759719845324"
      },
      {
        "source_id": "42",
        "source_url": "https://www.nature.com/articles/s41392-020-00222-7"
      },
      {
        "source_id": "43",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4447122/"
      },
      {
        "source_id": "44",
        "source_url": "https://genesdev.cshlp.org/content/suppl/2006/04/17/gad.381706.DC1/BrackenSuppTable3.pdf"
      },
      {
        "source_id": "45",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4729067/"
      },
      {
        "source_id": "46",
        "source_url": "https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.1538"
      },
      {
        "source_id": "47",
        "source_url": "https://www.kegg.jp/kegg-bin/get_htext?htext=ko00001.keg&query=myc"
      },
      {
        "source_id": "48",
        "source_url": "https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2017.00031/full"
      },
      {
        "source_id": "49",
        "source_url": "https://en.wikipedia.org/wiki/Myelin_oligodendrocyte_glycoprotein"
      },
      {
        "source_id": "50",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3218606/"
      },
      {
        "source_id": "51",
        "source_url": "https://www.nature.com/articles/s41467-021-27462-7"
      },
      {
        "source_id": "52",
        "source_url": "https://pubmed.ncbi.nlm.nih.gov/2649509/"
      },
      {
        "source_id": "53",
        "source_url": "https://www.tandfonline.com/doi/abs/10.4161/cam.5.5.17949"
      },
      {
        "source_id": "54",
        "source_url": "https://pubmed.ncbi.nlm.nih.gov/34880248/"
      },
      {
        "source_id": "55",
        "source_url": "https://academic.oup.com/neuro-oncology/article/27/Supplement_5/v462/8319745"
      },
      {
        "source_id": "56",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11850250/"
      },
      {
        "source_id": "57",
        "source_url": "https://pubmed.ncbi.nlm.nih.gov/17041011/"
      },
      {
        "source_id": "58",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5458289/"
      },
      {
        "source_id": "59",
        "source_url": "https://www.nature.com/articles/s41523-020-00190-9"
      },
      {
        "source_id": "60",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3929113/"
      }
    ],
    "duration_seconds": null
  }
}